Literature DB >> 19855091

HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.

Junkui Ai1, Yujuan Wang, Javid A Dar, June Liu, Lingqi Liu, Joel B Nelson, Zhou Wang.   

Abstract

The development of castration-resistant prostate cancer (PCa) requires that under castration conditions, the androgen receptor (AR) remains active and thus nuclear. Heat shock protein 90 (Hsp90) plays a key role in androgen-induced and -independent nuclear localization and activation of AR. Histone deacetylase 6 (HDAC6) is implicated, but has not been proven, in regulating AR activity via modulating Hsp90 acetylation. Here, we report that knockdown of HDAC6 in C4-2 cells using short hairpin RNA impaired ligand-independent nuclear localization of endogenous AR and inhibited PSA expression and cell growth in the absence or presence of dihydrotestosterone (DHT). The dose-response curve of DHT-stimulated C4-2 colony formation was shifted by shHDAC6 such that approximately 10-fold higher concentration of DHT is required, indicating a requirement for HDAC6 in AR hypersensitivity. HDAC6 knockdown also inhibited C4-2 xenograft tumor establishment in castrated, but not in testes-intact, nude mice. Studies using HDAC6-deficient mouse embryonic fibroblasts cells showed that inhibition of AR nuclear localization by HDAC6 knockdown can be largely alleviated by expressing a deacetylation mimic Hsp90 mutant. Taken together, our studies suggest that HDAC6 regulates AR hypersensitivity and nuclear localization, mainly via modulating HSP90 acetylation. Targeting HDAC6 alone or in combination with other therapeutic approaches is a promising new strategy for prevention and/or treatment of castration-resistant PCa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19855091      PMCID: PMC2796151          DOI: 10.1210/me.2009-0188

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  52 in total

Review 1.  Principles for modulation of the nuclear receptor superfamily.

Authors:  Hinrich Gronemeyer; Jan-Ake Gustafsson; Vincent Laudet
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

Review 2.  Androgen receptor signaling in androgen-refractory prostate cancer.

Authors:  M E Grossmann; H Huang; D J Tindall
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

3.  Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo.

Authors:  W Fischle; F Dequiedt; M Fillion; M J Hendzel; W Voelter; E Verdin
Journal:  J Biol Chem       Date:  2001-07-20       Impact factor: 5.157

4.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

Authors:  David B Solit; Fuzhong F Zheng; Maria Drobnjak; Pamela N Münster; Brian Higgins; David Verbel; Glenn Heller; William Tong; Carlos Cordon-Cardo; David B Agus; Howard I Scher; Neal Rosen
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

5.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

Authors:  C Huggins; C V Hodges
Journal:  CA Cancer J Clin       Date:  1972 Jul-Aug       Impact factor: 508.702

6.  Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.

Authors:  Shashwati Basak; Deepa Pookot; Emily J Noonan; Rajvir Dahiya
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

7.  DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.

Authors:  T J Walton; G Li; R Seth; S E McArdle; M C Bishop; R C Rees
Journal:  Prostate       Date:  2008-02-01       Impact factor: 4.104

8.  Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor.

Authors:  Anthony J Saporita; Qiuheng Zhang; Neema Navai; Zehra Dincer; Junghyun Hahn; Xiaoyan Cai; Zhou Wang
Journal:  J Biol Chem       Date:  2003-08-15       Impact factor: 5.157

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling.

Authors:  Vikram D Kekatpure; Andrew J Dannenberg; Kotha Subbaramaiah
Journal:  J Biol Chem       Date:  2009-01-21       Impact factor: 5.157

View more
  49 in total

1.  Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.

Authors:  Katherine J O'Malley; Gabrielle Langmann; Junkui Ai; Raquel Ramos-Garcia; Robert L Vessella; Zhou Wang
Journal:  Prostate       Date:  2011-12-07       Impact factor: 4.104

Review 2.  Post-translational modifications of Hsp90 and translating the chaperone code.

Authors:  Sarah J Backe; Rebecca A Sager; Mark R Woodford; Alan M Makedon; Mehdi Mollapour
Journal:  J Biol Chem       Date:  2020-06-11       Impact factor: 5.157

3.  SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.

Authors:  Qiangui Bu; Lijing Cui; Juan Li; Xin Du; Waiyi Zou; Ke Ding; Jingxuan Pan
Journal:  Cancer Biol Ther       Date:  2014-04-23       Impact factor: 4.742

4.  Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.

Authors:  C T Chan; J Qi; W Smith; R Paranol; R Mazitschek; N West; R Reeves; G Chiosis; S L Schreiber; J E Bradner; R Paulmurugan; S S Gambhir
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

Review 5.  Phytochemicals from cruciferous vegetables, epigenetics, and prostate cancer prevention.

Authors:  Gregory W Watson; Laura M Beaver; David E Williams; Roderick H Dashwood; Emily Ho
Journal:  AAPS J       Date:  2013-06-26       Impact factor: 4.009

6.  Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.

Authors:  Ayesha A Shafi; Marc B Cox; Nancy L Weigel
Journal:  Steroids       Date:  2013-02-01       Impact factor: 2.668

7.  N-terminal domain of the androgen receptor contains a region that can promote cytoplasmic localization.

Authors:  Javid A Dar; Kurtis Eisermann; Khalid Z Masoodi; Junkui Ai; Dan Wang; Tyler Severance; Sharanya D Sampath-Kumar; Zhou Wang
Journal:  J Steroid Biochem Mol Biol       Date:  2013-10-04       Impact factor: 4.292

8.  CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.

Authors:  Huiying Sun; Sanjay N Mediwala; Adam T Szafran; Michael A Mancini; Marco Marcelli
Journal:  Horm Cancer       Date:  2016-03-08       Impact factor: 3.869

Review 9.  Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.

Authors:  Shuyang Chen; Nianli Sang
Journal:  J Biomed Biotechnol       Date:  2010-12-05

10.  Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate.

Authors:  Fei Su; Bruna R S Correa; Jianhua Luo; Ricardo Z N Vencio; Laura E Pascal; Zhou Wang
Journal:  Cancer Microenviron       Date:  2013-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.